Notably, high-risk patients demonstrated enhanced sensitivity to immunotherapy, as indicated by decreased tumor immune dysfunction and exclusion (TIDE) scores and increased expression of the immune checkpoints PD-1 and CTLA4. This evidence concerns the gene PDCD1 and neoplasm.